4-(3-chlorophenyl)-2-methylthiazol-5-ylamine | 1247687-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-chlorophenyl)-2-methylthiazol-5-ylamine
• 英文别名: 4-(3-Chlorophenyl)-2-methylthiazol-5-amine；4-(3-chlorophenyl)-2-methyl-1,3-thiazol-5-amine
• CAS: 1247687-32-6
• 化学式: C₁₀H₉ClN₂S
• 分子量: 224.714
• InChiKey: CEXXCGFETXVIBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloropyrazolo[1,5-a]pyrimidine-3-carbonyl chloride 、 4-(3-chlorophenyl)-2-methylthiazol-5-ylamine 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以62%的产率得到5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid [4-(3-chlorophenyl)-2-methylthiazol-5-yl]amide
  参考文献：
  名称：

  Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors

  摘要：

  The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in disc-ova-ring selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibit-or of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of 7j. In a SET2 xenograft model that is dependent on Jak2 for growth, 7j demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.

  DOI：

  10.1021/jm3012239
• 作为产物：
  描述：

  DL-3-chlorophenylglycine nitrile hydrochloride 、 乙醛 在 sulfur 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以73%的产率得到4-(3-chlorophenyl)-2-methylthiazol-5-ylamine
  参考文献：
  名称：

  Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors

  摘要：

  The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in disc-ova-ring selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibit-or of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of 7j. In a SET2 xenograft model that is dependent on Jak2 for growth, 7j demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.

  DOI：

  10.1021/jm3012239

文献信息

• INHIBITORS OF IAP
  申请人：Cohen Frederick

  公开号：US20120202750A1

  公开（公告）日：2012-08-09

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R 1 , R 2 , R 3 , R 4 , R 4 ′, R 5 , R 5 ′, R 6 and R 6 ′ are as described herein.

  该发明提供了新型IAP抑制剂，可用作治疗恶性肿瘤的治疗剂，其中化合物具有一般式I：其中X、Y、A、R1、R2、R3、R4、R4'、R5、R5'、R6和R6'如本文所述。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Genentech, Inc.

  公开号：US20140107099A1

  公开（公告）日：2014-04-17

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  本发明提供了JAK激酶抑制剂Ia的公式，其对映体、对映异构体或其药学上可接受的盐，其中R1，R2，R7和Z在此定义，以及包括公式Ia化合物和药学上可接受的载体、佐剂或载体的制药组合物，以及用于治疗或减轻患者对JAK激酶活性抑制敏感的疾病或病情严重程度的方法。
• US8637526B2
  申请人：——

  公开号：US8637526B2

  公开（公告）日：2014-01-28
• US8980837B2
  申请人：——

  公开号：US8980837B2

  公开（公告）日：2015-03-17